Evidence map›Paper›PMID 42388475›Full record

ArticleFrontiers in medicine2026

Severe probable immune checkpoint inhibitor-related pneumonitis after thoracic radiotherapy complicated by acute pulmonary embolism in lung squamous cell carcinoma: a case report.

Fangping Luo, Wanli Zhu, Yali Yu, Hongling Hu, Yingshan Cui, Haiqing Pan

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fangping LuoDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.
Wanli ZhuDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.
Yali YuDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.
Hongling HuDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.
Yingshan CuiDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.
Haiqing PanDepartment of Radiotherapy, Jinhua Municipal Central Hospital, Jinhua, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitor-related pneumonitis (CIP) is a potentially life-threatening adverse event in lung cancer. We report a case of severe probable CIP complicated by acute pulmonary embolism (PE) in a 76-year-old man with stage IIIA lung squamous cell carcinoma after chemoimmunotherapy and thoracic radiotherapy. He developed progressive dyspnea and severe hypoxemia. Serial chest computed tomography (CT) showed bilateral interstitial and ground-glass abnormalities beyond the radiation field, favoring probable CIP, although superimposed infection and obstructive pneumonia could not be fully excluded. During hospitalization, CT pulmonary angiography confirmed acute PE, and lower-extremity ultrasound suggested calf venous thrombosis. The patient required high-flow nasal cannula and received methylprednisolone, tocilizumab, intravenous immunoglobulin, mycophenolate mofetil, antimicrobial therapy, and therapeutic anticoagulation. Despite partial clinical improvement, serial chest CT demonstrated continued radiographic progression. This case highlights the need for dynamic differential diagnosis, multidisciplinary management, and close bedside monitoring in complex post-radiotherapy CIP.

Indexed as

high-flow nasal cannulaimmune checkpoint inhibitor-related pneumonitislung squamous cell carcinomapulmonary embolismthoracic radiotherapy

Identifiers

PMID42388475
PMCPMC13319016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.